Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists. METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to receive either long-term treatment with a beta-blocker (metoprolol or bisoprolol) or no beta-blocker treatment. The primary end point was a composite of death from any cause or new myocardial infarction. RESULTS: From September 2017 through May 2023, a total of 5020 patients were enrolled (95.4% of whom were from Sweden). The median follow-up was 3.5 years (interquartile range, 2.2 to 4.7). A primary end-point event occurred in 199 of 2508 patients (7.9%) in the beta-blocker group and in 208 of 2512 patients (8.3%) in the no-beta-blocker group (hazard ratio, 0.96; 95% confidence interval, 0.79 to 1.16; P = 0.64). Beta-blocker treatment did not appear to lead to a lower cumulative incidence of the secondary end points (death from any cause, 3.9% in the beta-blocker group and 4.1% in the no-beta-blocker group; death from cardiovascular causes, 1.5% and 1.3%, respectively; myocardial infarction, 4.5% and 4.7%; hospitalization for atrial fibrillation, 1.1% and 1.4%; and hospitalization for heart failure, 0.8% and 0.9%). With regard to safety end points, hospitalization for bradycardia, second- or third-degree atrioventricular block, hypotension, syncope, or implantation of a pacemaker occurred in 3.4% of the patients in the beta-blocker group and in 3.2% of those in the no-beta-blocker group; hospitalization for asthma or chronic obstructive pulmonary disease in 0.6% and 0.6%, respectively; and hospitalization for stroke in 1.4% and 1.8%. CONCLUSIONS: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, NCT03278509.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742c84 · Cited by 2,250
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION
Hjalmarson, Å., Herlitz, J., Málek, I., Rydén, L., Vedin, A., Waldenström, A., Wedel, H., Elmfeldt, D., Holmberg, S., Nyberg, G., et al. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91101-6 · Cited by 1,117
Jernberg, T., Attebring, M. F., Hambraeus, K., Ivert, T., James, S., Jeppsson, A., Lagerqvist, B., Lindahl, B., Stenestrand, U., & Wallentin, L. (2010) · Heart · doi:10.1136/hrt.2010.198804 · Cited by 773
Self-citationCleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J., Coats, A. J. S., Manzano, L., McMurray, J. J. V., Ruschitzka, F., van Veldhuisen, D. J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx564 · Cited by 659
Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials
Bangalore, S., Makani, H., Radford, M., Thakur, K., Toklu, B., Katz, S. D., DiNicolantonio, J. J., Devereaux, P. J., Alexander, K. P., Wetterslev, J., et al. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.05.032 · Cited by 315
Dondo, T. B., Hall, M., West, R. M., Jernberg, T., Lindahl, B., Bueno, H., Danchin, N., Deanfield, J. E., Hemingway, H., Fox, K. A. A., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.578 · Cited by 235
Self-citationEffect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction
Goldberger, J. J., Bonow, R. O., Cuffe, M. S., Liu, L., Rosenberg, Y., Shah, P. K., Smith, S. C., & Subacius, H. P. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.047 · Cited by 160
Dahl Aarvik, M., Sandven, I., Dondo, T. B., Gale, C. P., Ruddox, V., Munkhaugen, J., Atar, D., & Otterstad, J. E. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy034 · Cited by 125
Huang, B., Huang, F., Zuo, Z., Liao, Y., Heng, Y., Wang, P., Gui, Y.-Y., Xia, T., Xin, Z.-M., Liu, W. Y., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.02.057 · Cited by 95
Hambræus, K., Tydén, P., & Lindahl, B. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315585293 · Cited by 91
Self-citationJoo, S., Kim, S., Choi, J., Park, H.-K., Beom, J. W., Lee, J.-G., Chae, S. C., Kim, H.-S., Kim, Y. J., Cho, M., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa029 · Cited by 80
Rosselló, X., Raposeiras‐Roubín, S., Latini, R., Domínguez‐Rodríguez, A., Barrabés, J. A., Sanchez, P. L., Anguita, M. P., Fernández‐Vázquez, F., Pascual-Figal, D. A., Hernández, J. M. D. L. T., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab060 · Cited by 76
Shore, S., Jones, P. G., Maddox, T. M., Bradley, S. M., Stolker, J. M., Arnold, S. V., Parashar, S., Peterson, P. N., Bhatt, D. L., Spertus, J. A., et al. (2015) · Heart · doi:10.1136/heartjnl-2014-306754 · Cited by 60
Munkhaugen, J., Ruddox, V. D. B., Halvorsen, S., Dammen, T., Fagerland, M. W., Hernæs, K. H., Vethe, N. T., Prescott, E., Jensen, S. E., Rødevand, O., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.10.005 · Cited by 59
Kristensen, A. M. D., Bovin, A., Zwisler, A., Cerquira, C., Torp-Pedersen, C. T., Bøtker, H. E., Gustafsson, I., Veien, K. T., Thomsen, K. K., Olsen, M. H., et al. (2020) · Trials · doi:10.1186/s13063-020-4214-6 · Cited by 58
Self-citationMisumida, N., Harjai, K. J., Kernis, S. J., & Kanei, Y. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415608011 · Cited by 46
Raposeiras‐Roubín, S., Abu‐Assi, E., Diéguez, A. R., González-Ferreiro, R., López-López, A., Bouzas‐Cruz, N., Castiñeira-Busto, M., Peña, C., García‐Acuña, J. M., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.07.029 · Cited by 38
Yndigegn, T., Lindahl, B., Alfredsson, J., Benatar, J. R., Brandin, L., Erlinge, D., Haaga, U., Held, C., Johansson, P., Karlström, P., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac070 · Cited by 36
Self-citationMars, K., Wallert, J., Held, C., Humphries, S., Pingel, R., Jernberg, T., Olsson, E. M. G., & Hofmann, R. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaa002 · Cited by 28
Self-citation
Cited by
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Metadata
- Authors
- Yndigegn, T., Lindahl, B., Mars, K., Alfredsson, J., Benatar, J., Brandin, L., Erlinge, D., Hallen, O., Held, C., Hjalmarsson, P., Johansson, P., Karlström, P., Kellerth, T., Marandi, T., Ravn-Fischer, A., Sundström, J., Östlund, O., Hofmann, R., & Jernberg, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-18
- Volume
- 390
- Issue
- 15
- Pages
- 1372-1381
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4394061993
- Cited by
- 317
- References
- 23
- FWCI
- 84.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.